AbbVie's new launches Skyrizi, Rinvoq aren't getting enough credit: analyst

AbbVie's new launches Skyrizi, Rinvoq aren't getting enough credit: analyst

Source: 
Fierce Pharma
snippet: 

AbbVie has held high hopes for newcomers Skyrizi and Rinvoq as post-Allergan merger business drivers with the ongoing decline of Humira. But with prescription figures and market access tracking way ahead of expectations, did AbbVie know those two meds would be doing this well this fast?